GlobalData, Industry analysis specialist, has released its new report, "Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020", an essential and comprehensive source of information and analysis on the global Pulmonary Arterial Hypertension (PAH) therapeutics market. The report identifies and analyzes the key trends shaping and driving the global PAH therapeutics market, as well as treatment usage patterns in the global PAH therapeutics market. The competitive landscape is also covered, with insights into the emerging players expected to significantly alter the positions of the existing market leaders. An in-depth analysis of current pipeline products offers up valuable insights, and the report quantifies the unmet need in the global PAH therapeutics market as well as in the markets of the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, China, India and Russia, highlighting opportunities for future players.
This report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GlobalData's team of industry experts.
GlobalData estimated the global PAH therapeutics market was worth around $3.3 billion in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 38.6% from 2002 to 2011. PAH is a rare indication but despite the small patient volume, the market showed a tremendous growth in the historic period. This growth was due to the significant drug development activity corresponding to the launch of around eight premium priced drugs in the PAH therapeutics market from 2002 to 2011. Patient volume also increased during this period due to the increasing awareness.
The drugs used in the treatment of PAH are Tracleer (bosentan), Letairis (ambrisentan), Remodulin (treprostinil), Ventavis (iloprost), Revatio (sildenafil), Adcirca (tadalafil), Tyvaso (inhaled treprostinil) and Veletri (epoprostenol). The uptake of these drugs drove the market because of increase in Annual Cost of Therapy (ACOT) of PAH.
The global PAH therapeutics market is estimated to be worth $3.1 billion in 2020. It is forecast to show a negative CAGR of 0.6% from 2011 to 2020.
In 2011, the leading drugs in G7 market (the US, France, Germany, Italy, Spain, the UK and Japan) were Tracleer, Revatio, Letairis/Volibris and Remodulin with sales of $1,303.3m, $439.0m, $364.3m and $363.7m respectively.
For more information, please visit:
http://www.aarkstore.com/reports/Pulmonary-Arterial-Hypertension-PAH-Therapeutics-Global-Drug-Forecasts-and-Treatment-Analysis-to-2020-198726.html
Or email us at contact@aarkstore.com or call +918149852585
More reports
Aarkstore Enterprise
Tel : +912227453309
Mobile No:+08149852585
Email : contact@aarkstore.com
Website : http://www.aarkstore.com
Blog: http://www.emarketreports.com
Follow us on twitter: http://twitter.com/aarkstoredotcom
http://in.linkedin.com/in/aarkstore
http://www.facebook.com/aarkstoreenterprise
http://www.aarkstore.com/feeds/index.xml
http://www.aarkstore.com/feeds/globaldata.xml
This report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GlobalData's team of industry experts.
GlobalData estimated the global PAH therapeutics market was worth around $3.3 billion in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 38.6% from 2002 to 2011. PAH is a rare indication but despite the small patient volume, the market showed a tremendous growth in the historic period. This growth was due to the significant drug development activity corresponding to the launch of around eight premium priced drugs in the PAH therapeutics market from 2002 to 2011. Patient volume also increased during this period due to the increasing awareness.
The drugs used in the treatment of PAH are Tracleer (bosentan), Letairis (ambrisentan), Remodulin (treprostinil), Ventavis (iloprost), Revatio (sildenafil), Adcirca (tadalafil), Tyvaso (inhaled treprostinil) and Veletri (epoprostenol). The uptake of these drugs drove the market because of increase in Annual Cost of Therapy (ACOT) of PAH.
The global PAH therapeutics market is estimated to be worth $3.1 billion in 2020. It is forecast to show a negative CAGR of 0.6% from 2011 to 2020.
In 2011, the leading drugs in G7 market (the US, France, Germany, Italy, Spain, the UK and Japan) were Tracleer, Revatio, Letairis/Volibris and Remodulin with sales of $1,303.3m, $439.0m, $364.3m and $363.7m respectively.
For more information, please visit:
http://www.aarkstore.com/reports/Pulmonary-Arterial-Hypertension-PAH-Therapeutics-Global-Drug-Forecasts-and-Treatment-Analysis-to-2020-198726.html
Or email us at contact@aarkstore.com or call +918149852585
More reports
Aarkstore Enterprise
Tel : +912227453309
Mobile No:+08149852585
Email : contact@aarkstore.com
Website : http://www.aarkstore.com
Blog: http://www.emarketreports.com
Follow us on twitter: http://twitter.com/aarkstoredotcom
http://in.linkedin.com/in/aarkstore
http://www.facebook.com/aarkstoreenterprise
http://www.aarkstore.com/feeds/index.xml
http://www.aarkstore.com/feeds/globaldata.xml
No comments:
Post a Comment